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Anellovirusa non-enveloped human virus with a circular (∼3800 nt) ssDNA genome. TTV
transcription results in three viral mRNAs and six proteins, the function or antigenicity of which are unknown.
The six open reading frames of TTV genotype 6 were expressed in bacteria and insect cells. Expression of
the ORF1/1-encoded protein was inefﬁcient, while expression of the others was successful, with ORF1 and
ORF1/2 as arginine-rich region depleted.
All six recombinant TTV proteins were antigenic. Of healthy adults, 11/25 (44%) showed strong IgG
reactivity with one or more proteins. Four subjects, two of whom were genotype-6-DNA positive, were
followed. One of the latter showed concurrently a strong IgG response against the ORF1 protein. The other
showed appearance of IgG against the ORF2 protein concomitantly with resolution of the genotype-6 viremia.
The genotype-6 sequences remained unaltered for years, suggesting that some mechanisms other than amino
acid substitutions play a role in TTV immune evasion.
© 2008 Elsevier Inc. All rights reserved.Introduction
Torque teno virus (TTV) was found in 1997 from a Japanese patient
with hepatitis of unknown etiology (Nishizawa et al., 1997). TTV is a
small, non-enveloped virus containing an approximately 3.8 kb long,
circular negative-sense single-stranded DNA genome (Miyata et al.,
1999; Mushahwar et al., 1999). By genomic organization, TTV re-
sembles the chicken anemia virus (CAV) of the Circoviridae family, and
is currently classiﬁed as a member of a new, ﬂoating genus Anellovirus
(Biagini et al., 2004).
TTV shows a very high sequence variation, both at nucleotide and
amino acid levels. Several genotypes (differing by more than 30%)
have been identiﬁed, and form ﬁve major phylogenetic clusters
(Biagini et al., 2004). Also other TTV-like viruses have been char-
acterized: Torque teno minivirus (TTMV) (Takahashi et al., 2000) and
Torque tenomidivirus (TTMDV) or small anellovirus (SAV) (Jones et al.,
2005; Ninomiya et al., 2007a). All these viruses have genomes of
similar structure, yet with different sizes: 3.7–3.8 kb for TTV, 3.2 kb forDBJ/EMBL/GenBank databases
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l rights reserved.TTMDV/SAV, and 2.8–2.9 kb for TTMV (Biagini et al., 2007; Jones et al.,
2005; Ninomiya et al., 2007a; Takahashi et al., 2000).
Nearly all TTV research has been hitherto based on the detection of
viral DNA by PCR. It has become evident that this virus is spread
worldwide, with a ∼90% DNA prevalence in blood of asymptomatic
individuals (Abe et al., 1999; Huang et al., 2001; Kakkola et al., 2002;
Okamoto et al., 1999; Simmonds et al., 1999). Persistent infections and
co-infections with several genotypes are common (Ball et al., 1999;
Biagini et al., 1999; Irving et al., 1999; Lefrere et al., 2000; Sugiyama et
al., 1999). In addition, co-infections have been shown to occur with all
three TTV-like viruses in asymptomatic subjects (Biagini et al., 2006;
Ninomiya et al., 2007b).
The TTV genome consists of a 2.6 kb coding and 1.2 kb non-coding
region, the latter containing a GC-rich region, a promoter and trans-
criptional enhancer elements (Kamada et al., 2004; Miyata et al.,
1999; Mushahwar et al., 1999; Suzuki et al., 2004). A TATA-box and a
poly-A sequence deﬁne the coding area, in which overlapping open
reading frames (ORF) in all three frames are located (Erker et al.,
1999; Hijikata et al., 1999; Miyata et al., 1999). TTV has been shown to
produce by alternative splicing three mRNA species (Kamahora et al.,
2000), from which by alternative translation initiation six proteins
are produced (Qiu et al., 2005). The splice sites are well conserved
among various isolates (Peng et al., 2002). Even though variation
between the TTV genotypes is higher at the amino acid than at the
nucleotide level (Tanaka et al., 2000), the proteins encoded by
different genotypes have similar motifs, thus suggesting similar
functions.
Fig.1. Schematic presentation of the transcriptionmap of TTV genotype 6 (adapted from
Qiu et al., 2005). Thin lines represent introns, thick lines mRNA, and boxes translated
areas, the shading of which indicate different reading frames.
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encode a capsid protein (Takahashi et al., 1998). ORF1 has circovirus-
like replication-associated motifs (Erker et al., 1999; Tanaka et al.,
2001) and a CAV-like arginine-rich N-terminus (Mushahwar et al.,
1999; Okamoto et al., 1998; Takahashi et al., 1998) that has been
suggested to have DNA-binding activity and to function in packaging
of the viral DNA (Erker et al., 1999). ORF1 contains hypervariable
regions inwhich mutations leading to amino acid changes occur more
frequently than in the remaining part of the protein (Jelcic et al.,
2004; Nishizawa et al., 1999), suggesting immune evasion by
hypermutations.
ORF2 encodes a putative 200-amino-acid protein that has a
conserved amino acid motif (Hijikata et al., 1999; Peng et al., 2002).
This motif is part of the dual speciﬁcity phosphatase sequence, the
activity of which has been shown also in CAV and TTMV proteins
(Peters et al., 2002). In several genotypes a stop codon divides
ORF2 into two smaller frames, ORF2a and ORF2b. Even though the
ORF2b protein is less conserved than the ORF2a at the amino acid
level, it contains a CAV-like motif (Kakkola et al., 2002; Tanaka et
al., 2000; Ukita et al., 2000). Very recently the ORF2 protein was
shown to suppress the NF-κB pathway and thus to have putative
regulatory effects on innate and adaptive immunity (Zheng et al.,
2007).
The genotype-1a ORF3 protein [corresponding to ORF2/2 in (Qiu et
al., 2005), and ORF2-4 in (Kamahora et al., 2000)] has similarities with
a non-structural protein NS5A of hepatitis C virus (HCV). In Cos-1 cells,
this protein is produced in two forms, of which the slower-migrating
is phosphorylated at the C-terminal serine residues (Asabe et al.,
2001). The remaining three TTV proteins are essentially unknown, as
are the functions of all the six TTV proteins.
Only a few publications exist on TTV immunology and on the
expression of TTV proteins. Tanaka et al. (2000) expressed by an in
vitro transcription/translation method the putative ORF2 proteins,
showing the functional stop codon dividing the ORF2 into smaller
frames (Tanaka et al., 2000). ORF3 of genotype 1a was expressed for
phosphorylation studies in Cos-1 cells (Asabe et al., 2001). For
immunological studies, the putative capsid protein encoded by ORF1
has been produced in fragments. Lo et al. (1999) expressed in
prokaryotes ∼120 amino acids of ORF1 (the N22 region within the
C-terminal half), and found by immunoblots no IgG antibodies in
asymptomatic adults (Lo et al., 1999). Ott et al. (2000) expressed in
prokaryotes the C-terminal (aa 504–752) and Handa et al. (2000)
the N-terminal (aa 1–411) part of genotype-1 ORF1. These two
groups found by immunoblots antibodies in 98.6% of hepatitis
patients, blood donors, and asymptomatic children, and in 38% of
blood donors, respectively (Handa et al., 2000; Ott et al., 2000). We
have previously expressed in prokaryotes the two ORF2 proteins,
ORF2a and ORF2b, and detected IgM and IgG in 9–10% of
asymptomatic adults (Kakkola et al., 2002). In addition to immuno-
blotting, the existence of TTV antibodies in human sera has also
been shown by other methods, including immunoprecipitation and
immunocapture combined with PCR (Tsuda et al., 1999; Tsuda et al.,
2001).
As the methods in current use for detection of TTV infections
(restricted to acute and persisting, but not past) are PCR-based, little
is known of the TTV proteins and their antigenic potential.
Serological tests (measuring also past infections) would give
valuable information on immunological reactions in humans against
this highly prevalent, persisting, and potentially non-pathogenic
virus.
In our previous studies we have cloned in full length the genome
of TTV genotype 6 (Kakkola et al., 2007), and have identiﬁed the
proteins encoded (Qiu et al., 2005). The aim of the current study was
to express all the six TTV proteins in prokaryotic or baculoviral
expression systems for use as antigens in immunological and diag-
nostic studies.Results
Expression of the proteins in bacteria
Of the six protein coding regions (Fig. 1), altogether 11 constructs
were cloned into bacterial expression plasmids: ORF1ΔArg, ORF1-N,
ORF1-NΔArg, ORF1-C, ORF2, ORF2/2, ORF2/3, ORF1/1, ORF1/ΔArg,
ORF1/2 and ORF1/2ΔArg. The proteins were expressed in fusion with
GST in BL21 cells, and were analyzed by immunoblotting with GST
antibody. The Rosetta strain was attempted with the arginine-rich
proteins ORF1-N, ORF1/1 and ORF1/2, and with one arginine rich
region-depleted protein ORF1/1ΔArg, however, with no improvement
in expression levels. The successful expression conditions for each
construct are given in Table 1.
Since the expression of the arginine-rich ORF1 protein was
unsuccessful in our previous study (Kakkola et al., 2002), we decided
to express the protein in bacteria as arginine-depleted constructs
(ORF1ΔArg, ORF1-NΔArg) or in two parts (ORF1-N, ORF1-C). The ex-
pressions of the ORF1-NΔArg (∼63 kDa) and ORF1-C (∼69 kDa)
proteins were successful, as was the expression of ORF1ΔArg
(∼100 kDa), however, shorter forms of the latter protein were also
produced (Fig. 2). The expression of ORF1-N (∼70 kDa) was not
successful with any of the three media regardless of induction time.
For this construct only the Rosetta strain was used.
The expression of ORF1/1 (∼54 kDa) was of low level with any of the
three media, with any of the induction times, and with both of the
bacterial strains.Removalof thearginine-richpart (ORF1/1ΔArg;∼47kDa)
did not signiﬁcantly improve the expression (Fig. 2). The expression of
ORF1/2 (∼44 kDa) was likewise low in any of the expression conditions;
however, the removal of the arginine-rich part (ORF1/2ΔArg; ∼37 kDa)
resulted in major improvement of expression level (Fig. 2).
In our previous study we had expressed the fp2a (nt 104–253) and
fp2b (nt 237–707) proteins from the ORF2 coding area (Kakkola et al.,
2002). The ORF2 (nt 354–707; ∼44 kDa) encoded protein expressed in
this study corresponds to amino acids 40–118 of the previously
expressed fp2b, and was successfully expressed in prokaryotes (Fig. 2).
Also the expressions of ORF2/2 (∼57 kDa) and of ORF2/3 (∼56 kDa)
were successful (Fig. 2).
For expression of some constructs, room temperature and IPTG
concentration of 0.2 mM were also tried, but with no signiﬁcant
improvement. However, with the constructs that were prone to
forming shorter fragments in standard conditions, shifting of the
growth/induction time e.g. from 4/2 to 2/4 h brought a substantial
gain in protein yield (less fragmentation; data not shown).
Expression of the proteins in insect cells
Of the six protein coding regions, altogether 7 constructs, covering
all the reading frames in the coding area, were cloned into a
Table 1
Expression conditions used in prokaryotes for the TTV protein constructs
ORF1ΔArg ORF1-NΔArg ORF1-C ORF2 ORF2/2 ORF2/3 ORF1/1 ORF1/1ΔArg ORF1/2 ORF1/2ΔArg
Dilutiona 1:100 1:100 1:100 1:100 1:100 1:100 1:100 1:100 1:100 1:50
Growth mediumb TF LB YT LB LB LB TF YT TF LB
Growth/induction time in hoursc 5/2 6/1 5/2 4/2 4/2 4/2 5/2 5/2 5/2 2/4
a Dilution of over night grown bacteria for induction of expression.
b TF = Terriﬁc Broth, LB = L-Broth, YT = Yeast Extract Tryptone medium.
c e.g. 5/2 = bacteria grown for 5 h after dilution and subsequently induced (for expression) for 2 h.
184 L. Kakkola et al. / Virology 382 (2008) 182–189baculoviral expression plasmid: ORF1, ORF1ΔArg, ORF1-N, ORF1-C,
ORF2/2, ORF2/3 and ORF1/1. The proteins were expressed as GST-
6xHis-fusion proteins, and were analyzed by immunoblotting, ﬁrst
with the GST antibody.
The expression levels of ORF1-N (∼70 kDa) and ORF1/1 (∼54 kDa)
were of low level, while the expression of full-length ORF1 (∼110 kDa)
was unsuccessful. The expression of ORF1ΔArg (∼100 kDa), ORF1-C
(∼69 kDa), ORF2/2 (∼57 kDa) and ORF2/3 (∼56 kDa) were successful
and yielded adequate amounts of fusion proteins (Fig. 3).
IgG responses in human sera
To study the IgG seroprevalences in 21 humans, we used the best
protein constructs, i.e. the bacterially expressed ORF1-NΔArg, ORF1-
C, ORF2, ORF2/2, ORF2/3 and ORF1/2ΔArg, and the insect cell-derived
ORF1ΔArg, ORF1-N, ORF1-C, ORF2/2, ORF2/3 and ORF1/1. Follow-up
sera additionally obtained from 4 individuals were studied with the
same constructs, and with the bacterially expressed ORF1ΔArg and
ORF1/1ΔArg.
A sample was regarded as IgG positive only with an unequivocal
band of correct molecular size in immunoblot. Entirely negativeFig. 2. TTV proteins expressed in bacteria. Immunoblotting with anti-GST antibody.immunoblots were regarded as negative. Faint or barely visible bands,
or inconsistent results, were considered borderline (+/−).
The seroprevalences and the corresponding TTV DNA prevalences
(obtained with UTR-PCR) are shown in Table 2. Altogether 11/25 (44%)
subjects showed positive and 16 /25 (64%) showed borderline
reactivities with one or more of the expressed proteins. A representa-
tive sample is shown in Fig. 4. Of the 21 individuals (excluding follow-
up subjects), 5 (24%) were negative for all TTV antigens. The
prokaryotic and eukaryotic antigens gave similar results.
Of the 21 individuals, 18 were studied for each of the four ORF1
constructs. The remaining three individuals were studied only for the
bacterially expressed ORF1-C, and one of them also for ORF1ΔArg. If
any of the expressed ORF1 constructs showed positive or borderline
results, the sample was classiﬁed as ORF1-IgG positive or as border-
line, respectively. Of the 21 subjects, 3 /21 (14.3%) were ORF1-IgG
positive, whereas 11/21 (52.4%) were negative (Table 2). Interestingly,
all the ORF1 responses were towards the ORF1ΔArg and ORF1-C
proteins, and none towards ORF1-N (with or without the arginine-rich
region).
For the other proteins, positive responses were detected towards
the products of ORF2 in 6/21 (28.6%), ORF2/2 in 1/19 (5.3%), ORF2/3 in
5/21 (23.8%), ORF1/1 in 1/18 (5.6%), and ORF1/2 in 0/20 (0%) of the
subjects (Table 2). The 12 subjects (excluding those followed up), who
showed positive (n=6) or borderline (n=6) IgG responses towards the
ORF2-encoded protein, were compared with those of IgG responses
towards fp2a and fp2b in our previous study (Kakkola et al., 2002). All
eight fp2b seropositive subjects identiﬁed previously were in the
current study classiﬁed as ORF2 IgG positive or borderline, and four
additional subjects showed borderline IgG responses. Of the three
individuals who had shown IgG towards fp2a, one was ORF2 IgG
negative, and two, who also had IgG towards fp2b, were ORF2 IgG
positive.
Of the 21 subjects, 17 were tested by PCR for genotype-6 DNA in
serum, and two (11.8%) were found positive. Of these two, subject #23
showed IgG reactivity with ORF2, ORF2/2 and ORF2/3, was borderline
with ORF1-C, and was seronegative for ORF1/2 (the other constructsFig. 3. TTV proteins expressed in insect cells. Immunoblotting with anti-GST antibody.
Table 2
IgG seroprevalences with each TTV recombinant protein in TTV-DNA-positive and
negative subjects (by UTR PCR)
IgG positive IgG borderline IgG negative Total
IgG for ORF1a
PCR+ 2/21 (9.5%) 6/21 (28.6%) 10/21 (47.6%) 18/21 (85.7%)
PCR− 1/21 (4.8%) 1/21 (4.8%) 1/21 (4.8%) 3/21 (14.3%)
Total 3/21 (14.3%) 7/21 (33.3%) 11/21 (52.4%) 21/21 (100%)
IgG for ORF2
PCR+ 6/21 (28.6%) 5/21 (23.8%) 7/21 (33.3%) 18/21 (85.7%)
PCR− 0/21 (0%) 1/21 (4.8%) 2/21 (9.5%) 3/21 (14.3%)
Total 6/21 (28.6%) 6/21 (28.6%) 9/21 (42.9%) 21/21 (100%)
IgG for ORF2/2
PCR+ 1/19 (5.3%) 4/19 (21.1%) 11/19 (9.5%) 16/19 (57.9%)
PCR− 0/19 (0%) 0/19 (0%) 3/19 (4.8%) 3/19 (15.8%)
Total 1/19 (5.3%) 4/19 (21.1%) 14/19 (14.3%) 19/19 (100%)
IgG for ORF2/3
PCR+ 5/21 (23.8%) 2/21 (9.5%) 11/21 (52.4%) 18/21 (85.7%)
PCR− 0/21 (0%) 0/21 (0%) 3/21 (14.3%) 3/21 (14.3%)
Total 5/21 (23.8%) 2/21 (9.5%) 14/21 (66.7%) 21/21 (100%)
IgG for ORF1/1
PCR+ 1/18 (5.6%) 0/18 (0%) 14/18 (77.8%) 15/18 (83.3%)
PCR− 0/18 (0%) 0/18 (0%) 3/18 (16.7%) 3/18 (16.7%)
Total 1/18 (5.6%) 0/18 (0%) 5/18 (27.8%) 18/18 (100%)
IgG for ORF1/2b
PCR+ 0/20 (0%) 2/20 (10%) 15/20 (75%) 17/20 (85%)
PCR− 0/20 (0%) 0/20 (0%) 3/20 (15%) 3/20 (15%)
Total 0/20 (0%) 2/20 (10%) 18/20 (90%) 20/20 (100%)
IgG status for
any antigenc
8/21 (38%) 8/21 (38%) 5/21 (24%) 21/21 (100%)
a Any ORF1 construct.
b ORF1/2ΔArg construct was used, which has the N-terminal 62 aa arginine-rich
region deleted.
c Classiﬁed as positive if showed positive response to any of the antigens, classiﬁed as
negative if showed no response to any of the antigens.
Table 3
Follow-up of four subjects for IgG antibodies and for TTV DNA
Year IgG for
ORF1
IgG for
ORF2
IgG for
ORF2/2
IgG for
ORF2/3
IgG for
ORF1/1
IgG for
ORF1/2
TTV
DNA
Genotype-6
DNA
#2
2005 + − − − + + − −
2006 + − − − + + − −
#32
2000 + − − − + − + +
2005 + − − − + − + +
2006 + − − − + +/− + +
#80
2000 +/− − − − − − − −
2005 +/− − − − − − − −
2006 +/− − − − − − − −
#86
1993 − − − − − − + −
1996 − − − − − − + +
1998 − + − − − − + +
2001 − + − − − − + −
2005 − + − − − − + −
2006 − + − − − − + −
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ORF1-C, and was seronegative for all the other constructs.
Follow-up studies
Follow-up samples from four additional subjects were analyzed for
TTV DNA and for TTV antibodies (Table 3). Two subjects, #2 and #80,
negative for both TTV-DNA and TTV genotype-6 DNA, showed positive
or borderline ORF1-IgG results, respectively. Subject #2 was also IgG
positive for the ORF1/1 and ORF1/2 encoded proteins. Of note, subject
#2 had been TTV-DNA positive by UTR-PCR in an earlier sample from
1994 (Kakkola et al., 2002). Two subjects had in serum genotype-6Fig. 4. Example of immunoblotting with one human serum (subject #32 of the follow-
up group) showing strong IgG reactivity (arrows) against ORF1ΔArg and ORF1-C
proteins.DNA either persistently (#32) or transiently (#86). Subject #32 was
IgG positive for ORF1 and ORF1/1 throughout the follow-up. Subject
#86 experienced a seroconversion for ORF2-IgG in 1998, and
remained IgG positive thereafter, but was IgG negative for all the
other proteins. At the time of the seroconversion, the genotype-6 DNA
disappeared from circulation (Table 3).
Genotype-6 amplicons obtained and sequenced from these two
subjects, showed no major changes during follow-up. Of the seven
sequences obtained from the 1996 serum of subject #86, six showed
the same 8/223 nucleotide differences (leading to amino acid change
in three positions) and the seventh showed one additional difference
(also at amino acid level) compared to our genotype-6 clone. The same
8 nucleotide differences (and one additional, but not leading to amino
acid change) were present in 1998 (Kakkola et al., 2002). The
sequences of subject #32 (from whom the genotype-6 clone was
initially isolated in 1998) showed in 2000–2006 no nucleotide
differences compared to the genotype-6 clone, or only isolated
single-nucleotide changes (leading to amino acid changes only
twice). This person had in 1998 at least two additional TTV isolates
in circulation (Kakkola et al., 2002). The titers of genotype-6 DNA
(determined by end-point dilution of PCR followed by amplicon
hybridization) were stable over time: #32 and #86 had DNA titers of
10−1 and 100, respectively. Taken together, in subject #32 the
nucleotide sequence remained stable for 8 years (from 1998 to
2006) at the same titer. Throughout this time she also had antibodies
for ORF1. In subject #86 the nucleotide sequence remained stable for
the two years that the genotype-6 DNA was detectable in her serum.
Of note, upon disappearance from circulation of the genotype-6 DNA,
the ORF2-IgG antibodies appeared.
Discussion
In order to elucidate the immunology of TTV infections, we
expressed all six proteins of genotype 6, and used them as antigens in
immunoblots to detect the protein-speciﬁc IgG responses in human
sera.
Expression of TTV proteins
As in our previous study (Kakkola et al., 2002), the expression of
the putative capsid protein, ORF1, was not successful as an entire full-
length protein. Although in transfection studies the mRNA encoding
this protein has constituted as much as 60% of the total RNA, it has
been suggested that the amount of protein translated is low or that the
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were able to express this protein in two slightly overlapping parts and
also as an arginine-depleted construct.
In our previous study we expressed two proteins of the ORF2
region: the ORF2a and ORF2b-encoded proteins, the genes of which
are separated by a stop codon and a frame shift (Kakkola et al., 2002).
This stop codon interrupting ORF2 has been identiﬁed also in other,
though not all, TTV isolates (Kakkola et al., 2002; Tanaka et al., 2000).
Based on the transcriptionmap (Qiu et al., 2005), it is likely that due to
mRNA splicing, the ORF2a region is removed and the protein is not
produced. Nevertheless, it is possible that in cells of other types or
under some particular conditions this protein is expressed. The ORF2
expressed in this study is included in ORF2b, described earlier
(Kakkola et al., 2002), but is 39 amino acids shorter at the N-terminus.
The ORF1/2 and ORF2/2 proteins are highly enriched in C-terminal
serine residues. Asabe et al. (2001) showed that the ORF3 protein
(equaling to our ORF2/2) of genotype 1a occurs in immunoblots in two
forms that differ in phosphorylation state (Asabe et al., 2001). In our
immunoblots from insect cells the ORF2/2-encoded protein occurred
in multiple molecular sizes, possibly representing the differentially
phosphorylated forms. Whether similar phosphorylation occurs on
the ORF1/2-encoded protein is not known. In database searches TTV
proteins have shown resemblance to other proteins: Takahashi et al.
(2000) noted in serine-rich proteins of TTV and TTMV similarities with
topoisomerase (Takahashi et al., 2000), and Kamahora et al. (2000)
found in the ORF2-4 protein of genotype 1 (equaling to our ORF2/2)
similarities with transcription factors and RNA-binding motifs
(Kamahora et al., 2000). We were able to express the ORF2/3-encoded
protein in high amounts both in bacteria and in insect cells. This
protein equals to the ORF2–5 protein reported by Kamahora et al.
(2000), which also has been predicted to share properties with
transcription factors (Kamahora et al., 2000). However, no deﬁnitive
function has yet been assigned to any of these proteins.
In expression of the ORF1 and ORF1/2-encoded proteins, we noted
that the presence of the arginine-rich N-terminus (aa 1–62) reduces or
abolishes protein expression. The Rosetta strain of E. coli which co-
expresses tRNA for arginine codons, did not increase the yield. The
expression levels were however dramatically increased upon deletion
of this arginine-rich part. The expression of ORF1/1 was less
successful, for an unknown reason.
Among TTVs, additional splicing events and intragenomic rear-
rangements have been suggested to form yet additional ORFs (Leppik
et al., 2007). It is thus possible that different genotypes/genogroups of
TTV show differences in mRNA splicing and/or protein expression. In
addition, the transcription proﬁle could vary between cell types; for
example the activity of the promoter region seems to differ in various
cell types (Kamada et al., 2004; Suzuki et al., 2004). However, the
occurrence of additional mRNAs and ORFs, potentially leading to new
proteins, remains to be shown.
The prevalence of IgG
Based on previous reports, it is evident that some degree and form
of TTV immune activity occur in humans. IgG antibodies have been
shown by immunoprecipitation in some subjects after viremia (Tsuda
et al., 1999). By immunocapture combined with PCR, the kinetics of
IgM and IgG antibodies have been shown to follow the classical
course, i.e. short-lived IgM followed by long-lasting IgG (Tsuda et al.,
2001). TTV in serum has been found as immunocomplexed with IgG
(Itoh et al., 2000), especially during persistent infections (Nishizawa et
al., 1999). Interestingly, superinfection with a new TTV strain
decreased the immunocomplexes, and was followed by clearance of
the superinfecting strain. It was discussed that superinfections, as
opposed to primary/persistent infections, might be more effectively
cleared by preformed antibodies (Maggi et al., 2006). It has also been
estimated that over 90% of the TT viruses in circulation are cleared andreplenished daily by progeny viruses, thus indicating chronic active
infection (Maggi et al., 2001). It is evident that humans acquire TTV
very early in life; even transplacental transmission has been suggested
(Gerner et al., 2000; Matsubara et al., 2001; Morrica et al., 2000;
Saback et al., 1999). Infection during immune development could also
help the virus to establish persistence. Nevertheless, experimental
data on immune responses towards TTV is very scanty.
In this study we have detected with immunoblots in human sera
IgG antibodies against all the TTV proteins, suggesting that they all
are produced in vivo. The antibody pattern was different in each
individual, for an unknown reason. Ott et al. (2000) found a nearly
100% prevalence of antibodies towards the C-terminus of ORF1 (Ott et
al., 2000); in comparison, our ORF1 IgG prevalence of 48% (including
33% borderlines) was much lower. This could either reﬂect an
immunological difference between the TTV genotypes (genotype 1
vs. genotype 6) or be due to the methods used. The IgG prevalence of
38% detected by Handa et al. (2000) using as antigen the N-terminus
of genotype-1 ORF1 (Handa et al., 2000), is in the same order of
magnitude as our overall ORF1-IgG prevalence. Contradictory to that,
we did not detect antibody reactivity against the N-terminus; instead,
all our responses against the ORF1 encoded protein targeted the
C-terminus. It remains to be seen whether the immunological
differences are genotype-speciﬁc. The IgG results obtained with the
ORF2 antigen in this study correlated with the antibody responses
detected in our previous study (Kakkola et al., 2002), thereby further
conﬁrming the speciﬁcity of the IgG reactivities against the ORF2
protein.
In our previous studies we have shown that the genoprevalence of
genotype 6 in Finland is 4–8.6% (Kakkola et al., 2002; Kakkola et al.,
2004). In this study 44% of our subjects had IgG antibodies towards
one or more of the TTV genotype-6 proteins. Were TTV antibodies
genotype-speciﬁc, this seroprevalence could indeed reﬂect the
cumulative lifetime infection incidence of this particular virus type
in the Finnish population.
Follow-up study
We have previously (Kakkola et al., 2002) identiﬁed three
genotype-6 positive subjects, two of whom were here characterized
further. Subject #32 had been genotype-6 DNA positive for at least 8
years (1998–2006). This subject was strongly IgG positive for the ORF1
and ORF1/1 proteins for at least six years. Of note, the full-length clone
from which the proteins were expressed in this study had been
isolated from her serum in 1998. We wished to see whether the
genotype-6 DNA sequence would change during these years. We
found no major nucleotide changes, suggesting that the TTV sequence
of the ampliﬁed region remains unaltered regardless of functional B-
cell immunity. Interestingly, also the relative level of genotype-6 DNA
in her sera remained constant. Subject #86 was followed for 13 years.
Through these years she was positive for TTV DNA in general, and
experienced a temporary genotype-6 viremia, after which she
seroconverted to ORF2 IgG.
The ORF1 protein has been shown to contain within the amino
acids 275–402 hypervariable regions (HVRs) which have been
suggested to aid the virus in immune evasion and in establishment
of persistent infections (Jelcic et al., 2004; Luo et al., 2002; Nishizawa
et al., 1999; Umemura et al., 2002). Our amplicon sequence of
nucleotides 1918–2143 (amino acids 447–522) was outside of these
HVRs. Thus within the HVRs more mutations could possibly have
occurred than within the region observed here. Published data on
alterations in TTV sequences among persistently infected subjects are
controversial. It has been proposed that, during TTV persistence the
sequences change, isolates are cleared from circulation and replaced
by reinfection, or sequences remain the same, thereby indicating
either true persistence, and/or superinfections, as well as evolution of
quasispecies (Ball et al., 1999; Biagini et al., 1999; Gallian et al., 1999;
Table 4
Primers used for cloning the open reading frames into expression plasmids
Primer name
(and orientation)
5′–3′ primer sequence
(nt numbering according to AY666122)
Used for ampliﬁcation of
noARG tttgaattcATGcgcagacacagaaaaaaac ORF1ΔArg, ORF1-NΔArg
(forward) (nt 767–785)
RepCF tttgaattcaacacatggtacagaggcaatg ORF1-C (bacteria)
(forward) (nt 1613–1634)
RepCR tttcccgggttatgcatgggaagatagt ORF1, ORF1ΔArg, ORF1-C
(insect cells)(reverse) (nt 2791–2773)
3F tcggaattcATGgcctggtactggt ORF1, ORF1-N, ORF5
(outer PCR), ORF6(forward) (nt 581–596)
O1aSTOP tttcccgggttatcctggggacaggaatatg ORF1-N, ORF1-NΔArg
(reverse) (nt 1786–1768)
O1endATG tttgaattcATGaacacatggtacagaggcaatg ORF1-C (insect cells)
(forward) (nt 1613–1634)
Nsf ttttgaattcATGtggcagccacctacccag ORF2, ORF3 (outer PCR),
ORF4(forward) (nt 354–374)
2R tctaataaaggcggccgcccactg ORF2
(reverse) (nt 802–797)
Ns1rkor ttttcccgggttaaacataaagaccttgtt ORF3 (outer PCR),
ORF6, ORF6ΔArg(reverse) (nt 2810–2791)
ORF3srkorj ctggagaaagtgtaagagcatctg ORF3 (inner PCR),
ORF5 (inner PCR)(reverse) (nt 2504–2481)
ORF3sf gccgcagaatcgtccgac ORF3 (inner PCR),
ORF5 (inner PCR)(forward) (nt 696–703→2314–2324)
Ns2r ttttcccgggttaatgaaagccaagtttg ORF4
(reverse) (nt 2979–2964)
3R gctttgggcagcggccgctatgtgg ORF5 (outer PCR),
ORF5ΔArg(reverse) (nt 2921–2915)
noARG2 tttgaattcATGcgcgctcgccgcaga ORF5ΔArg, ORF6ΔArg
(forward) (nt 689–703)
The restriction sites are shown with bolded letters, the translation initiation codons
with capital letters and the translation stop codons with italics. Nucleotide numbers
correspond to the sequence complementary to AY666122, thus excluding restriction
enzyme sites and 5′ upstream sequences.
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(1999) suggested that in acute infection quasispecies do not exist,
while in chronic infection TTV sequences continuously evolve
(Nishizawa et al., 1999). Our follow-up data indicate that genotype-6
viremias can be either persistent or transient, with no nucleotide
changes within the ampliﬁed region of ORF1.
Conclusions
TTV is a minute virus, obviously lacking the genetic capacity of the
larger viruses for immune evasion. Nevertheless, TTV seems to be
adapted to its host very well, whereby the long-term virus-host co-
evolution could explain the existence of the numerous TTV genotypes
and the possible lack of strong immune responses. In order for us to
achieve a full picture of TTV and its interplay with our immunity, also
proteins of other genotypes need to be expressed and analyzed for
antibody isotypes and cross-reactivity, for conformational and linear
epitopes, and for afﬁnity/avidity. In addition, the role of T-cell function
in TTV infections needs to be elucidated. To begin with, we have
expressed all six proteins of TTV genotype 6, and shown them to be
immunoreactive with human antibodies.
Materials and methods
The transcription map of the full-length genotype-6 plasmid clone
has been determined in transfected 293 cells (Qiu et al., 2005) and is
shown in Fig. 1. The primers for (RT-)PCRs to obtain the cDNA
constructs for the expression of the proteins were designed based on
the transcription map. Nucleotide numbering is according to the TTV
HEL32 sequence, GenBank # AY666122.
Construction of expression plasmids
The cDNA constructs for protein expression in bacteria and in
insect cells were obtained with PCR and/or RT-PCR: ORF1 (nt 581–
2791), ORF1ΔArg (nt 767–2791, aa 63–737), ORF1-N (nt 581–1787, aa
1–402), ORF1-NΔArg (nt 767–1787, aa 63–402), ORF1-C (nt 1613–
2791, aa 344–737), ORF2 (nt 354–707), ORF1/1ΔArg (nt 689–703 and
2315–2791, aa 37–199) and ORF1/2ΔArg (nt 689–703 and 2505–2810,
aa 37–142), ORF2/3 (nt 354–703 and 2505–2982), ORF1/2 (nt 581–703
and 2505–2810), ORF2/2 (nt 354–703 and 2315–2810), and ORF1/1 (nt
581–703 and 2315–2791). For termination of translation, the stop
codon of the viral gene was utilized (i.e. the primer was designed
down stream of the stop codon or the primer overlapped with the
viral stop codon). Table 4 lists the primers used for cloning of the
cDNAs into expression plasmids.
PCRs to produce and amplify the cDNAs were done either with
Ampli Taq Gold (Applied Biosystems/Roche) or with the Expand High
Fidelity PCR system (Boehringer Mannheim/Roche) as recommended
by the manufacturer, and the templates were either the TTV genotype-
6 plasmid clone (pTTV) (Kakkola et al., 2007) or the cloned ORFs.
RT-PCRs to amplify the cDNAs were done either with OneTube
Titan RT-PCR System (Roche) or by RobusT II RT-PCR Kit (Finnzymes)
as recommended by the manufacturer, and the template was total
RNA isolated on day 3 from pTTV-transfected 293 or 293T cells
(Kakkola et al., 2007; Qiu et al., 2005).
The cloning of cDNAs into expression plasmids was done in E. coli
strain DH5α with standard restriction enzyme and ligation protocols.
For expression in bacteria, the cDNAs were cloned into pGEX-4T-1
(Amersham Pharmacia), and for expression in insect cells, the cDNAs
were cloned into pAcGHLT-A Baculovirus Transfer Vector (BD Bio-
sciences). The plasmid clones were isolated from the bacteria with
QIAprep SpinMiniprep Kit (Qiagen) andwith GenElute Endotoxin-free
Maxiprep Plasmid Puriﬁcation Kit (Sigma), respectively.
All the plasmid clones were sequenced and conﬁrmed to be in
frame with fusion proteins and to contain exactly the same nucleotidesequence as in the TTV genotype-6 isolate HEL32 (GenBank accession
number AY666122). The sequencing reactions were done using the
ABI Prism 3100 Genetic Analyzer (Applied Biosystems) at the se-
quencing core facility of the Haartman Institute, University of Helsinki,
Finland.
Expression of proteins in bacteria
For prokaryotic expression, TTV genotype-6 cDNAs were cloned in
fusion with a glutathione S-transferase protein (GST-protein). For
protein expression, the plasmid clones were transformed into E. coli
strain BL21, and for the expression of arginine-rich proteins, into E. coli
strain Rosetta (Novagen). The bacteria were grown over night in L-
Broth medium at +37 °C, followed by 2 h at +37 °C as diluted 1:100.
Protein expression was then induced with 0.4 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) for 4–6 h. Optimization of the expres-
sion conditions was done with the constructs that showed low level
expression with our standard expression conditions; when necessary,
growth time after dilution (2–6 h) and induction times (1–6 h)
(marked as e.g. 5/2 in Table 1), induction temperatures (room tem-
perature or +37 °C), and growth media (L-Broth, YT or Terriﬁc Broth)
were optimized. The expressed proteins were analyzed with SDS-
PAGE and immunoblotting.
Expression of proteins in insect cells
For eukaryotic expression, TTV genotype-6 cDNAs were cloned in
fusion with GST and with hexahistidine (GST-6xHis-tag). Spodoptera
frugiperda (Sf9) insect cells were transfected by Fugene-6 Transfection
Reagent (Roche) with Linearized Baculovirus DNA (BD Biosciences)
and with the vector containing the TTV-cDNA insert. The transfected
Sf9 cells produced recombinant baculoviruses encoding the GST-
6xHis-fusion proteins. For large scale protein expression, Sf9 and/or
Tricoplusia ni (HighFive) insect cells were infected with recombinant
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and immunoblotting.
Immunoblotting
The proteins of the crude cell lysates were separated on 10%
SDS-PAGE, and transferred to Protran nitrocellulose membranes
(Schleicher & Schüell) at 15 V for 30 min with Trans-Blot SD Elec-
trophoretic Transfer Cell (Bio-Rad). The membranes were blocked
with 5% fat-free milk powder (Valio) and 0.2% Triton X-100 in PBS. For
immunodetection of the GST fusion proteins, the primary antibody
was mouse α-GST Ab-1 (LabVision) in 1:445 dilution, and the second-
ary antibody was peroxidase-conjugated rabbit α-mouse IgG (DAKO)
at dilution 1:500.
For analysis of TTV-speciﬁc IgG antibodies in human sera, the
samples were diluted 1:50 in PBS containing 5%milk powder and 0.2%
Triton X-100 and were used as primary antibody. The secondary
antibody was peroxidase-conjugated rabbit α-human IgG (DAKO)
diluted 1:500.
Bound antibodies were detected with hydrogen peroxide and
diaminobenzidine (DAB). Bacteria expressing the sole GST, or insect
cells infected with the GST-6xHis-recombinant baculovirus were
used as positive controls for expression, and as negative controls in
immunoblotting in addition to the uninduced or non-infected cells.
Serum samples
Sera were obtained, with informed consent, from 25 non-
symptomatic Finnish adults (Kakkola et al., 2002). In addition,
sequential serum samples were obtained from four individuals. This
study was approved by the Ethical Committee of the Helsinki
University Central Hospital.
Universal PCR and genotype-6 PCR
Isolation of DNA from sera, universal PCR (UTR-PCR) and genotype-
6 PCR were done as described previously (Kakkola et al., 2002). The
amplicons obtained from the genotype-6 positive sera were puriﬁed
with High Pure PCR Product Puriﬁcation Kit (Roche), and cloned into
pSTBlue-1 AccepTor Vector (Novagen) in E. coli DH5α. Of each
amplicon, 4–7 bacterial clones containing a genotype-6 sequence
were isolated and sequenced. One amplicon was also sequenced
directly from the genotype-6 PCR. The amount of genotype-6 DNA in
sera was semi-quantiﬁed with end point dilution of the PCR template.
For sensitivity and speciﬁcity, the PCR amplicons were additionally
analyzed by Southern hybridizationwith a digoxigenin (DIG) -labelled
PCR-generated probe (Kakkola et al., 2002).
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